Phaseline

Targets › GNRH1R

GNRH1R: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Oncology; next expected readout Jul 2028.

Open in Phaseline: the race on GNRH1R, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Mayo ClinicGonadotropin-releasing Hormone Analog
GnRH receptor agonist; suppresses LH and FSH to reduce testosterone production
GNRH1RPhase 2Oligometastatic Prostate CarcinomaJul 2028

Conditions

Oligometastatic Prostate Carcinoma (1)

Modalities

mixed (1)

Companies

Mayo Clinic (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.